By continuing to use the site, you allow the use of Cookies and agree to the privacy policy.
.,о.,р..и.:г,.и.,н.;н.,а;,л.. .,н.:а,.х.,о.,д.;и.,т..с.:я,, ..н.;а., .,k;,i..b.:e,;r.,i.,s.,.;.r.:u,

Antitumor agents - protein kinase inhibitors

Pharmaceutical group preparations

Substance Drugs
Abemaciclib |
Afatinib
Akalabrutinib
Alectinib
Asciminib
Axitinib
Binimetinib
Bosutinib |
Cabozantinib
Capmatinib
Ceritinib
Cobimetinib
Crizotinib
Dabrafenib |
Dacomitinib
Dasatinib | | | |
Duvelisib
Encorafenib
Entrectinib
Erlotinib | | | | | |
Everolimus | | | | | | |
Gefitinib | | | | | | | | | | | |
Gilteritinib
Ibrutinib
Imatinib | | | | | | | | | | | | | | | | | | | | | | |
Ixazomib |
Lapatinib | |
Larotrectinib
Lenvatinib |
Lorlatinib
Midostaurin
Nilotinib | | |
Nintedanib
Osimertinib | |
Palbociclib |
Pazopanib | | | | |
Ponatinib
Regorafenib
Ribociklib |
Ruxolitinib
Selumetinib
Sorafenib | | | | | | |
Sunitinib | | | | |
Temsirolimus
Trametinib
Vandetanib
Vemurafenib
Zanubrutinib
The active substance is not described

Tree of pharmacological groups

Description

There is no detailed description, see related
42a96bb5c8a2acfb07fc866444b97bf1
Available only when using PRO account
Content moderator: Vasin A. S.